

Figure 4A






Figure 4B

	PMA	ACE			
	(nM)	(mg/ml)			
veh	100	1	3	5	


Involucrin



Loricrin



TGase 1



β -actin






Figure 5A

veh		PMA (100 nM)				ACE (3 mg/ml)					
6	0.5	1	2	6	0.5	1	2	6	hr		


p-EGFR^{Y1068}




p-PKC β II^{S660}




EGFR



PKC β II



p-AKT^{T308}



β -actin



AKT




Figure 5B




Figure 5C

ACE (3 mg/ml)	vehicle			Osimertinib (1 μ M)			hr
	—	1	3	—	1	3	

p-EGFR^{Y1068}

p-mTOR^{S2448}

EGFR

mTOR

p-AKT^{T308}

p-PKC β II^{S660}

AKT

PKC β II

β -actin











Figure 6A





Figure 6B

veh		PMA		ACE		ACE		Osi		Osi		Osi		Osi		hr
		(100 nM)		(1 mg/ml)		(3 mg/ml)		(1 mM)		+PMA		+ACE		+ACE		
36		24	36	24	36	24	36	24	36	24	36	24	36	24	36	

Involucrin



β -actin

